Kwong Rhonda A, Kalish Larry H, Nguyen Tuan V, Kench James G, Bova Ronaldo J, Cole Ian E, Musgrove Elizabeth A, Sutherland Robert L
Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.
Clin Cancer Res. 2005 Jun 1;11(11):4107-16. doi: 10.1158/1078-0432.CCR-04-2036.
The INK4A-ARF locus at chromosome 9p21 is frequently altered in head and neck squamous cell carcinoma (SCC) and encodes two distinct tumor suppressors, p16(INK4A) and p14(ARF). This study addressed the role of p14(ARF) as a potential prognostic marker in this disease.
p14(ARF) protein expression was assessed by immunohistochemistry in a cohort of 140 patients with SCC of the anterior tongue. Using univariate and multivariate Cox's proportional hazards models, the outcomes examined were time to disease recurrence or death, with or without clinicopathologic covariates, including nodal status, disease stage, treatment status, Ki-67 staining, and molecular markers with known functional or genetic relationships with p14(ARF) (p16(INK4A), p53, pRb, p21(WAF1/CIP1), E2F-1).
On multivariate analysis, p14(ARF) positivity (nucleolar p14(ARF) staining and/or nuclear p14(ARF) staining in >/=30% of tumor cells) was an independent predictor of improved disease-free survival (DFS; P = 0.002) and overall survival (OS; P = 0.002). This was further enhanced when p14(ARF) positivity was cosegregated with positive (>/=1%) p16(INK4A) staining (DFS, P < 0.001; OS, P < 0.001). Patients whose cancers were p14(ARF) negative and p53 positive (>50%) had the poorest outcome (DFS, P < 0.001; OS, P < 0.001) of any patient subgroup analyzed.
These data show that in patients with SCC of the tongue, combined nuclear and nucleolar expression of p14(ARF) protein predicts for improved DFS and OS independent of established prognostic markers.
位于9号染色体p21区域的INK4A-ARF基因座在头颈部鳞状细胞癌(SCC)中经常发生改变,该基因座编码两种不同的肿瘤抑制因子,即p16(INK4A)和p14(ARF)。本研究探讨了p14(ARF)作为该疾病潜在预后标志物的作用。
通过免疫组织化学方法对140例舌前部鳞状细胞癌患者进行p14(ARF)蛋白表达评估。使用单因素和多因素Cox比例风险模型,所检测的结局指标为疾病复发或死亡时间,同时纳入或不纳入临床病理协变量,包括淋巴结状态、疾病分期、治疗状态、Ki-67染色以及与p14(ARF)具有已知功能或遗传关系的分子标志物(p16(INK4A)、p53、pRb、p21(WAF1/CIP1)、E2F-1)。
多因素分析显示,p14(ARF)阳性(≥30%的肿瘤细胞出现核仁p14(ARF)染色和/或细胞核p14(ARF)染色)是无病生存期(DFS;P = 0.002)和总生存期(OS;P = 0.002)改善的独立预测因素。当p14(ARF)阳性与p16(INK4A)阳性(≥1%)染色同时出现时,这种预测作用进一步增强(DFS,P < 0.001;OS,P < 0.001)。在所有分析的患者亚组中癌症为p14(ARF)阴性且p53阳性(>50%)的患者预后最差(DFS,P < 0.001;OS,P < 0.001)。
这些数据表明,在舌鳞状细胞癌患者中,p14(ARF)蛋白的细胞核和核仁联合表达可预测DFS和OS的改善,且独立于已确立的预后标志物。